Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

CG Oncology Appoints Isabel Kalofonos as Chief Commercial Officer

PUBLIC · CGONOct 13, 2026
New to company · from Crinetics Pharmaceuticals“Most recently, she served as Chief Commercial Officer of Crinetics Pharmaceuticals (acquired by Vertex Pharmaceuticals)”

Position

Chief Commercial Officer

Company

CG Oncology

Isabel Kalofonos
isabel.kalofonos@cgoncology.com
IrvineBiotechnologyHealth CareTherapeutics

Description

CG Oncology announced the appointment of Isabel Kalofonos as Chief Commercial Officer to lead its commercial strategy. Ms. Kalofonos brings over 20 years of experience in the biopharmaceutical industry and will help advance the company's efforts toward the potential launch of cretostimogene grenadenorepvec.

Company Information

Company

CG Oncology

Location

Irvine, California, United States

About

CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).

Fundz sees it the moment CG Oncology changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Ambaw
Senior decision-maker at this company
••••••••@••••••••

See Ambaw's verified email →

Aman
Senior decision-maker at this company
••••••••@••••••••

See Aman's verified email →

Isabel
Likely contact at this company
••••••••@••••••••

See Isabel's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for CG Oncology's next move

Learn about Strategic plan

CG Oncology changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.